Cramer stated on Mad Money at the end of last week's trading that Recursion's stock performance has "been disastrous" since ...

Around the middle of February, shares of Recursion Pharmaceuticals bounded higher after the company reported phase 2 results ...

Explore why Recursion Pharmaceuticals' AI-driven drug discovery faces challenges in revenue growth, governance, and investor ...

FDA 批准了 REC-4539 的新药试验申请，允许开始针对小细胞肺癌和其他实体肿瘤适应症的 1/2 期试验。 FDA 已批准新型 LSD1 抑制剂 REC-4539 的 IND 申请，启动针对 SCLC 和其他实体瘤适应症的 1/2 期临床试验。

Recursion制药 (NASDAQ: RXRX)公布2024年第四季度业绩,每股亏损0.53美元,高于预期的0.41美元亏损。公司收入为455万美元,低于预期的1340万美元。消息公布后,Recursion股价盘前下跌13.04%。

英为财情Investing.com - Recursion Pharmaceuticals (NASDAQ: RXRX)星期五发布了第四季度的财报，数据显示，公司营收逊于分析师的预期，每股收益低于分析师的预期。 在该公司发布的最新财报中，公司每股收益为$-0.53，总营收为$4.55M，而此前英为财情Investing.com对分析师的调查显示，分析师预期该公司的营收为$13.4M，每股收益为$- ...

Recursion Pharmaceuticals (NasdaqGS:RXRX) recently announced a $500 million Follow-on Equity Offering and revealed mixed earnings results for Q4 2024, which showed declining quarterly sales and ...

Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) were sinking 8.2% lower as of 10:57 a.m. ET on Monday. The clinical-stage biotech company, which is a pioneer in using artificial intelligence ...

We recently published an article titled Jim Cramer’s Latest Lightning Round: 8 Stocks in Focus. In this article, we are going ...

Recursion Pharmaceuticals is a leader in TechBio with potential to bring in $200M in near-term milestones and $20B in future ...

Learn more about whether Recursion Pharmaceuticals, Inc. or Veracyte, Inc. is a better investment based on AAII's A+ Investor ...

The Gothic Recursion collection may seem like original designs from Marvel Rivals, but Black Panther's newest skin has comic ...